Research And Development In Biotechnology (Except Nanobiotechnology) federal obligations in FY2025

Biotechnology R&D overlapping FY2025 — NAICS 541714

This page is a join: Research And Development In Biotechnology (Except Nanobiotechnology) (NAICS 541714) and FY2025. $947,986,750.05 is the obligation sum on that pair. It is not the government-wide FY2025 total on FY2025 federal spending, not every industry’s book on All industries, and not cash already paid. FY2025 is a closed fiscal year in the yearlyTrend series used here; later ingests can still restate the cell. Correlation is not causation: a large FY2025 cell does not prove federal demand caused activity in biotechnology r&d, or the reverse.

FY2025 yearlyTrend is that fiscal year’s obligation sum tagged to NAICS 541714. A different fiscal year for the same code is a separate overlay. Calendar-year industry statistics are not this time key. NAICS 541714 is the industry parent without a year filter. FY2025 federal spending is the fiscal-year parent without this NAICS filter. All spending ties lists other pairs. Campaign-finance tables are a different dataset; donations do not fund these USAspending obligations.

Research And Development In Biotechnology (Except Nanobiotechnology) as the industry side

NAICS 541714 is Research And Development In Biotechnology (Except Nanobiotechnology). The code marks research and development in biotechnology except nanobiotechnology. This packet lists no award recipients and no contractor names. Confusing this join with NAICS 541713 nanotechnology R&D or a trial-count dashboard would be a different table. Packet facts on the industry side are the name Research And Development In Biotechnology (Except Nanobiotechnology), code 541714, all-year obligations $19,013,172,722.03, and 2,378 awards. Any other recipient, program mix, or vendor list would be invented.

Readers sometimes treat a NAICS-year total as a budget Congress passed for a named activity. $947,986,750.05 is not that. It is the USAspending obligation rollup tagged to Research And Development In Biotechnology (Except Nanobiotechnology) in FY2025. Sibling or neighboring codes such as NAICS 541713 research and development in nanotechnology sit outside this cell. Cite Research And Development In Biotechnology (Except Nanobiotechnology) and FY2025. Do not invent vendors or award recipients.

FY2025 on biotechnology R&D (except nanobiotechnology) rows

Fiscal year 2025 is the yearlyTrend year key. It is not a calendar year and not a count of establishments in biotechnology r&d. Awards that carry a different year sit outside this cell even if the NAICS is still 541714. FY2025 obligations of $947,986,750.05 are about 5.0% of the industry’s $19,013,172,722.03 all-year obligation total in this extract. Do not treat the all-year $19,013,172,722.03 as if it were the FY2025 headline.

FY2025 federal spending shows how Research And Development In Biotechnology (Except Nanobiotechnology) sits beside other industries in the same fiscal year. This packet has no outlay total, no recipient roster, and no awarding-agency split. All industries is the directory of NAICS hubs. Programs, performers, and molecules are unpublished on this packet.

2,378 awards as an industry table, not a lab census

The extract lists 2,378 awards on the Research And Development In Biotechnology (Except Nanobiotechnology) table. That is an industry-level award-record count, not a FY2025-only census published on this packet. Dividing $947,986,750.05 by 2,378 would mix a year cell with an all-year row count, so this page does not treat that quotient as a typical FY2025 invoice. Unique vendors are unpublished. Modifications can add rows without naming a new company.

Trial-count rankings the join cannot support

An obligation is a legal commitment. An outlay is a payment. $947,986,750.05 is the former. Citing it as cash already cleared in FY2025 over-reads the field. The join cannot say that FY2025 specialized in biotechnology r&d because of federal demand. Keep $947,986,750.05 labeled as Research And Development In Biotechnology (Except Nanobiotechnology) obligations in FY2025. It is not nanotechnology R&D, an NIH Reporter list, or a clinical-trial registry.

Hubs for NAICS 541714 × FY2025

Open NAICS 541714 for the industry rollup, FY2025 federal spending for the fiscal-year rollup, All industries for other NAICS hubs, and All spending ties for other pairs. None of those links convert this cell into NAICS 541713 nanotechnology R&D or a trial-count dashboard, into outlays this packet omits, or into a contractor list. Cite both sides: Research And Development In Biotechnology (Except Nanobiotechnology) and FY2025, $947,986,750.05, USAspending.gov, obligations only. NAICS 541714 remains the industry key.

Questions

How much did Research And Development In Biotechnology (Except Nanobiotechnology) show in federal obligations in FY2025?

USAspending.gov records $947,986,750.05 in Research And Development In Biotechnology (Except Nanobiotechnology) obligations for FY2025 (NAICS 541714). That is an obligation aggregate for the industry-year pair, not an outlay and not the government-wide FY2025 total.

Is biotechnology R&D FY2025 an outlay?

No. $947,986,750.05 is a yearlyTrend obligation sum, not an outlay. Payments from the Treasury can lag or differ. This packet has no outlay total for Research And Development In Biotechnology (Except Nanobiotechnology) in FY2025. Original filings remain on USAspending.gov.

Does 2,378 awards mean 2,378 biotech labs?

No. 2,378 is the industry table’s award-record count in this extract, not a published FY2025-only recipient census. Unique vendors and places are unpublished. Modifications can add rows. Original filings remain on USAspending.gov. Keep both the NAICS code and the fiscal year in the citation.

Which pages parent Research And Development In Biotechnology (Except Nanobiotechnology) FY2025?

NAICS 541714 is the industry parent. FY2025 federal spending is the FY2025 parent. All industries lists NAICS hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes Research And Development In Biotechnology (Except Nanobiotechnology) × FY2025 at $947,986,750.05.